JAM
FLXN

JW Asset Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

JW Asset Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,000
Closed -$269K – 44
2017
Q1 		$269K Buy
+10,000
New +$204K 0.06% 37

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

JW Asset Management's FLXN Position: Q2 2017 in Review

JW Asset Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2017, closing a stake of 10,000 shares — an estimated $269K sold.

JW Asset Management first reported a position in FLXN in Q1 2017 and held it in 1 quarter. The position peaked at $269K in Q1 2017. 100 funds tracked by Wall St. Rank hold FLXN as of Q2 2017.

  • JW Asset Management reported no remaining Flexion Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • JW Asset Management sold 10,000 Flexion Therapeutics, Inc. shares in Q2 2017, an estimated $269K.
  • JW Asset Management first reported a position in Flexion Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • JW Asset Management's Flexion Therapeutics, Inc. position peaked at $269K in Q1 2017.
  • 100 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2017.

Based on JW Asset Management's 13F filing for Q2 2017, filed 4 Aug 2017.